Navigation Links
Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
Date:9/9/2008

ternal medicine with a subspecialty in endocrinology and metabolism.

"We are very pleased to have Ken join Intarcia Therapeutics to lead our hepatitis C and diabetes clinical development efforts," said Alice Leung. "Ken's drug development experience and expertise in the areas of diabetes and metabolic diseases are tremendous assets as we prepare to initiate clinical development of ITCA 650 for the treatment of type 2 diabetes. We look to his significant clinical and development expertise as we bring Omega DUROS therapy into later stages of development as well as expand the Company's pipeline in the metabolic diseases area."

Intarcia is currently conducting a phase 1 study of Omega DUROS therapy in combination with ribavirin for the treatment of patients with HCV genotype-1 who have failed prior standard of care treatment. In addition, Intarcia is preparing to initiate a phase 1 clinical trial of ITCA 650 in the first quarter of 2009 for the treatment of type 2 diabetes. Both of these programs use Intarcia's proprietary subcutaneous DUROS drug delivery technology that provides continuous and consistent administration of drug therapy.

Dr. Luskey said, "Intarcia represents a very unique opportunity. I believe the proven advantages of the DUROS delivery technology hold great potential in developing more effective treatments for many chronic diseases, including hepatitis C and type 2 diabetes. I am very excited to join Intarcia at this stage of the Company's development and look forward to directing clinical programs to fulfill the potential of DUROS delivery in these two disease areas."

About Intarcia

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with chronic diseases in which there are significant unmet medical needs. Intarcia's drug development expertise and competitive edge are complemented by its ability to stabilize macromolecules and to deliver them in a constant and consistent ma
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. Announces Reverse Stock Split
2. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
3. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
4. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
5. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
6. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
7. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
8. Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
9. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
10. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
11. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... (PRWEB) September 18, 2014 OMICS ... the globe to participate in the ‘Open Access ... articles to OMICS Group Pharma Journals ... one of the fastest emerging Sciences, accelerating with ... healthcare services across the globe. The industry is ...
(Date:9/18/2014)... September 18, 2014 SeqLL Inc., ... (tSMS™) technology, announced today the closing of a ... led by Genomic Diagnostic Technologies, will increase the ... applications. , Founded in March 2013 by Daniel ... Analyst at Helicos BioSciences, SeqLL has continued to ...
(Date:9/18/2014)... group of rare diseases that afflict skeletal growth ... hits at the fetal stage and is caused ... encoding fibroblast growth factor receptor 3 (FGFR3) has ... thanatophoric dysplasia (TD), a skeletal dysplasia that cause ... lethal, and achondroplasia (ACH), which causes stunted growth ...
(Date:9/18/2014)... can be pretty expensive. Now a team led by ... open-source library of designs that will let scientists slash ... the syringe pump. , Syringe pumps are used to ... or mixing chemicals in a reaction. They can also ... Pearce and his team of Michigan Tech students published ...
Breaking Biology Technology:Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3Doing science just got cheaper -- and faster 2
... Up in the sky. It's a bird. It's a plane. It's ... denial in a single bound. Indeed, lately the media has been ... to result from the mass exodus of Baby Boomers from the ... believe that this trend and its impacts on businesses are black ...
... Milwaukee, Wis. - The National Cancer Institute ... Medical College of Wisconsin to study the growth ... second successful renewal of the grant that was first awarded ... ongoing principal investigator. , ,She and other investigators are developing ...
... This is the ninth in a series of articles ... sectors. The most recent article focused on worker classification. ... The idea is developed. Lawyers and accountants are on ... is formed. The name has been chosen. Perhaps workers, ...
Cached Biology Technology:Shades of gray: Business impacts of an aging workforce 2Shades of gray: Business impacts of an aging workforce 3Shades of gray: Business impacts of an aging workforce 4Shades of gray: Business impacts of an aging workforce 5Shades of gray: Business impacts of an aging workforce 6Early Stage, Step 9: Raising capital in the securities landscape 2Early Stage, Step 9: Raising capital in the securities landscape 3Early Stage, Step 9: Raising capital in the securities landscape 4
(Date:9/18/2014)... too stressed they are often grouchy, grumpy, nasty, distracted ... at EPFL have just highlighted a fundamental synaptic mechanism ... loss of social skills and cognitive impairment. When triggered ... in the brain. This was revealed by a work ... Sandi,s team went to look for answers in a ...
(Date:9/18/2014)... are the ideal animal in which to study the ... ocean into tens of thousands of freshwater streams and ... to adapt to the new environment. , Breeding studies ... turned up one of the genes that controls tooth ... gene,s regulation in a freshwater population is associated with ...
(Date:9/18/2014)... invisible is probably the ultimate form of camouflage: you ... And this strategy is not as uncommon as you ... Baltimore County, USA, explains that the larval life stages ... one part of the anatomy that most creatures cannot ... eyes have to shield each individual eye unit with ...
Breaking Biology News(10 mins):How stress tears us apart 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3Transparent larvae hide opaque eyes behind reflections 2
... and American Board of Internal Medicine (ABIM) announce the ... performance evaluation tools for blood specialists. , ... ABIM certification, ASH and ABIM have co-developed the Hematology ... to complete their practice performance assessment requirement for recertification. ...
... research project which could revolutionise the diagnosis and treatment ... four-year project, the results of which are now being ... means of identifying the two most deadly forms of ... for practitioners. , The implications for improving children's health ...
... to ferns to create a novel energy scavenging device that ... provide a method for powering micro and nano devices with ... works," said Michel Maharbiz, assistant professor of electrical engineering and ... the device. "If you build these things they will move. ...
Cached Biology News:New tool helps blood specialists improve patient care 2Hope for major advance in fighting world killer disease 2Hope for major advance in fighting world killer disease 3Ferns provide model for tiny motors powered by evaporation 2
... a simple high performance method for removing ... without significant dilution of protein solution. ... Detergent-OUT Spin column and collect detergent free ... removing detergent from a maximum of 0.2 ...
... Chemicon Detergent-OUT SDS Kit is a simple ... protein solutions. Removes detergents without significant ... the protein solution on the Detergent-OUT Spin ... Med columns are suitable for removing ...
... from frozen embedded tissue blocks, which are ... ensure the highest quality. Tissues of each ... sectioned at a thickness of 7 microns ... large (3-5 mm in diameter) in comparison ...
... Zyagen tissue microarrays are derived from frozen ... rigorous quality control procedures to ensure the ... manually assembled in one block, sectioned at ... coated slides. Sections are large (3-5mm in ...
Biology Products: